ProMIS Neurosciences (PMN)
NASDAQ:PMN
PMN Stock Chart & Stats
$8.12
-$0.04(-3.74%)
At close: 4:00 PM EST
$8.12
-$0.04(-3.74%)
Day’s Range― - ―
52-Week Range$6.27 - $39.75
Previous CloseN/A
Volume32.49K
Average Volume (3M)819.50K
Market Cap
$31.73M
Enterprise Value-$6.10B
Total Cash (Recent Filing)$6.15B
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.37
Next Earnings
May 18, 2026EPS Estimate
-1.06Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.11
Shares Outstanding2,152,397
10 Day Avg. Volume1,049,009
30 Day Avg. Volume819,497
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)-9.53
Price to Sales (P/S)0.00
P/FCF Ratio-0.43
Enterprise Value/Market Cap-192.18
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda0.15
Forecast
1Y Price Target
$35.00Price Target Upside331.03% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-6.31
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
PIPE Financing Extends RunwayThe $75M PIPE materially improves funding visibility and reduces the immediacy of fundraising risk, covering completion of Phase 1b for PMN310 and enabling planned blinded six‑month and 12‑month top-line data in 2026. That funding materially de-risks near‑term execution and clinical milestones over the next 12–24 months.
Low Reported LeverageReported absence of debt across recent years lowers fixed financial obligations and interest burden, preserving flexibility to allocate capital toward R&D and clinical programs. Low leverage supports the company’s ability to absorb trial-related expenses and to access equity financing with fewer creditor constraints.
Focused Therapeutic Pipeline (PMN310)A concentrated pipeline targeting toxic misfolded proteins addresses core disease biology for Alzheimer’s and ALS, offering structural product-market fit if clinical efficacy is demonstrated. Advancing PMN310 and a subcutaneous formulation shows strategic focus on developable, potentially scalable therapeutics with long-term commercial relevance.
Bears Say
No Recurring RevenueAs a pre‑commercial biotech with negligible revenue, the company lacks internally generated cash to fund operations or scale R&D. This structural revenue gap forces ongoing reliance on external financing, increases dilution risk for shareholders, and limits resilience against adverse trial outcomes over the medium term.
Persistent Cash BurnSustained negative operating and free cash flow—and a sharp 2025 deterioration—means the company must repeatedly access capital markets to sustain programs. That pattern elevates execution risk, can delay or downscale trials if financing tightens, and increases long‑term dilution and dependency on investor appetite.
Negative Shareholders' Equity EpisodesRepeated periods of negative equity signal balance‑sheet strain and reduce financial flexibility. Negative book equity can limit borrowing capacity, complicate partnerships or licensing negotiations, and heighten insolvency concerns if future financing becomes constrained, making sustained program advancement more uncertain.
ProMIS Neurosciences News
PMN FAQ
What was ProMIS Neurosciences’s price range in the past 12 months?
ProMIS Neurosciences lowest stock price was $6.27 and its highest was $39.75 in the past 12 months.
What is ProMIS Neurosciences’s market cap?
ProMIS Neurosciences’s market cap is $31.73M.
When is ProMIS Neurosciences’s upcoming earnings report date?
ProMIS Neurosciences’s upcoming earnings report date is May 18, 2026 which is in 51 days.
How were ProMIS Neurosciences’s earnings last quarter?
ProMIS Neurosciences released its earnings results on Mar 25, 2026. The company reported -$4.11 earnings per share for the quarter, beating the consensus estimate of -$4.66 by $0.55.
Is ProMIS Neurosciences overvalued?
According to Wall Street analysts ProMIS Neurosciences’s price is currently Undervalued.
Does ProMIS Neurosciences pay dividends?
ProMIS Neurosciences does not currently pay dividends.
What is ProMIS Neurosciences’s EPS estimate?
ProMIS Neurosciences’s EPS estimate is -1.06.
How many shares outstanding does ProMIS Neurosciences have?
ProMIS Neurosciences has 2,152,397 shares outstanding.
What happened to ProMIS Neurosciences’s price movement after its last earnings report?
ProMIS Neurosciences reported an EPS of -$4.11 in its last earnings report, beating expectations of -$4.66. Following the earnings report the stock price went down -9.065%.
Which hedge fund is a major shareholder of ProMIS Neurosciences?
Currently, no hedge funds are holding shares in PMN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
ProMIS Neurosciences Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$35.00 (331.03% Upside)
$35.00 (331.03% Upside)
Insider Transactions
Bought Shares
Worth $8.7M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.8%
Last 30 Days ▼ 10.0%
Last 30 Days ▼ 10.0%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-58.18%
12-Months-Change
Fundamentals
Return on Equity
9999.00%
Trailing 12-Months
Asset Growth
-51.45%
Trailing 12-Months
Company Description
ProMIS Neurosciences
ProMIS Neurosciences (PMN) is a biotechnology company focused on the discovery and development of precision therapeutics for neurodegenerative diseases, particularly Alzheimer's disease and amyotrophic lateral sclerosis (ALS). The company utilizes its proprietary technology platform to selectively target misfolded proteins implicated in these diseases, aiming to develop disease-modifying treatments. ProMIS Neurosciences operates primarily in the biotechnology and pharmaceutical sectors, leveraging advanced scientific research to address unmet medical needs in neurodegenerative conditions.
PMN Stock 12 Month Forecast
Average Price Target
$35.00
▲(331.03% Upside)